Abstract
Background
Equol, a metabolite of diadzein, is produced by some intestinal bacteria. Equol acts as an estrogen receptor agonist and has been reported to have several beneficial health effects. Leukocytes play an important role in the pathogenesis of autoimmune, metabolic, and cardiovascular diseases. Decreased leukocyte mitochondrial DNA (mtDNA) content, as an index of mitochondrial function, is associated with metabolic syndrome, bone mineral density, and aging. The possible association between equol production and leukocyte mitochondrial function has not been studied to date. Therefore, we investigated whether equol production is associated with leukocyte mtDNA copy number in postmenopausal women.
Methods
This observational cross-sectional study included 71 postmenopausal women. They completed a lifestyle questionnaire and medical history. In addition, a dietary assessment using a 24-hour recall method and food frequency questionnaire, anthropometric evaluation, and blood sampling were conducted. Serum equol concentration was measured in the fasting state. Leukocyte mtDNA copy number was measured by real-time polymerase chain reaction.
Results
Among older females, 33.8% were equol producers. The leukocyte mtDNA copy number was lower in non-equol producers versus equol producers. Furthermore, the leukocyte mtDNA copy number was positively associated with the serum equol concentration (r=0.42, P<0.01). Stepwise multiple regression analysis showed that equol production (β=47.864, P<0.01) was an independent factor associated with mtDNA copy number.
REFERENCES
1.Larkin T., Price WE., Astheimer L. The key importance of soy isoflavone bioavailability to understanding health benefits. Crit Rev Food Sci Nutr. 2008. 48(6):538–52.
2.Hong KW., Ko KP., Ahn Y., Kim CS., Park SJ., Park JK, et al. Epidemiological profiles between equol producers and non-producers: a genomewide association study of the equol-producing phenotype. Genes Nutr. 2012. 7(4):567–74.
3.Franke AA., Lai JF., Halm BM., Pagano I., Kono N., Mack WJ, et al. Equol production changes over time in postmenopausal women. J Nutr Biochem. 2012. 23(6):573–9.
4.Setchell KD., Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr. 2006. 136(8):2188–93.
5.Aso T., Uchiyama S., Matsumura Y., Taguchi M., Nozaki M., Takamatsu K, et al. A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health (Larchmt). 2012. 21(1):92–100.
6.Jackson RL., Greiwe JS., Schwen RJ. Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist. Nutr Rev. 2011. 69(8):432–48.
7.Long J., He P., Shen Y., Li R. New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-β. J Alzheimers Dis. 2012. 30(3):545–58.
8.Kim JH., Im JA., Lee DC. The relationship between leukocyte mitochondrial DNA contents and metabolic syndrome in postmenopausal women. Menopause. 2012. 19(5):582–7.
9.Huang CH., Su SL., Hsieh MC., Cheng WL., Chang CC., Wu HL, et al. Depleted leukocyte mitochondrial DNA copy number in metabolic syndrome. J Atheroscler Thromb. 2011. 18(10):867–73.
10.Kim JH., Lee DC. Mitochondrial DNA copy number in peripheral blood is associated with femoral neck bone mineral density in postmenopausal women. J Rheumatol. 2012. 39(7):1465–72.
11.Simpkins JW., Yi KD., Yang SH., Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta. 2010. 1800(10):1113–20.
12.Borrás C., Gambini J., López-Grueso R., Pallardó FV., Viña J. Direct antioxidant and protective effect of estradiol on isolated mitochondria. Biochim Biophys Acta. 2010. 1802(1):205–11.
13.Levey AS., Coresh J., Greene T., Stevens LA., Zhang YL., Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006. 145(4):247–54.
14.Lee MJ., Kim JH. Estimated dietary isoflavone intake among Korean adults. Nutr Res Pract. 2007. 1(3):206–11.
15.Brouwers E., L'homme R., Al-Maharik N., Lapcík O., Hampl R., Wähälä K; K, et al. Time-resolved fluoroimmunoassay for equol in plasma and urine. J Steroid Biochem Mol Biol. 2003. 84(5):577–88.
16.Wong A., Cortopassi G. Reproducible quantitative PCR of mitochondrial and nuclear DNA copy number using the LightCycler. Methods Mol Biol. 2002. 197:129–37.
17.Setchell KD. Soy isoflavones--benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001. 20(5 Suppl):354S–62S. discussion 381S-3S.
18.Ko TF., Tsai HS., Lin SM., Liu CD., Learn SP., Chiou RY. GC-MS determined distribution of urinary equol producers as affected by age, gender, and repeated ingestions of soymilk. J Food Sci. 2010. 75(9):H306–10.
Table 1.
Equol producer (n=24) | Non-equol producer (n=47) | |
---|---|---|
Age, y | 71.6±4.4 | 69.9±3.7 |
Body mass index, kg/m2 | 25.62.8 | 24.73.2 |
Waist-hip ratio | 0.9±0.1 | 0.9±0.1 |
Total body fat, % | 35.6±6.2 | 34.5±7.0 |
Total body lean mass, kg | 21.0±2.6 | 19.6±2.3 |
Systolic blood pressure, mmHg | 127.6±11.9 | 129.4±11.7 |
Diastolic blood pressure, mmHg | 72.3±9.4 | 74.8±9.2 |
Fasting glucose, mg/dL | 101.4±18.2 | 102.8±16.0 |
Fasting insulin, μIU/mL | 6.9±3.0 | 6.7±2.9 |
HOMA-IR | 1.7±0.8 | 1.7±0.8 |
Total cholesterol, mg/dL | 199.2±41.2 | 202.5±46.3 |
Triglyceride, mg/dLb | 106.5 (64.0-131.0) | 127 (81-127) |
HDL-cholesterol, mg/dL | 51.9±10.5 | 51.1±9.8 |
LDL-cholesterol, mg/dL | 121.1±34.5 | 123.5±37.4 |
Estimated GFR, mL/min | 97.5±19.7 | 93.8±17.4 |
Leukocyte, /μL | 5,662.8±1,410.8 | 5,862.5±1,473.0 |
Hs-CRP, mg/mLb | 0.6 (0.3-1.3) | 0.8 (0.4-2.6) |
TSH, μIU/mL | 1.9±1.1 | 2.2±1.1 |
25-OH vitamin D, ng/mL | 12.5±5.2 | 12.2±6.1 |
Total energy intake, kcal/d | 1,488.9±283.4 | 1,587.7±314.8 |
Protein intake, % kcal | 15.9±2.0 | 16.0±2.7 |
Isoflavone intake, mg/db | 38.3 (13.9-59.5) | 25.5 (13.4-41.0) |
Current smoker | 1 (4.2) | 0 |
Alcohol consumptionc | 4 (16.7) | 6 (12.8) |
Regular exercise | 12 (50.0) | 20 (42.6) |
Medication | ||
Hypertension | 10 (41.7) | 20 (42.6) |
Diabetes | 3 (12.5) | 7 (14.9) |
Dyslipidemia | 4 (16.7) | 8 (17.0) |
Table 2.
Variables | r | Pb |
---|---|---|
Age | -0.20 | 0.040 |
Body mass index | -0.12 | 0.240 |
Waist hip ratio | -0.20 | 0.050 |
Total body fat | 0.01 | 0.930 |
Total lean body mass | 0.16 | 0.110 |
Systolic blood pressure | -0.26 | 0.005 |
Diastolic blood pressure | -0.10 | 0.320 |
Fasting glucose | -0.17 | 0.070 |
Fasting insulin | -0.01 | 0.910 |
HOMA-IR | -0.06 | 0.550 |
Total cholesterol | -0.06 | 0.540 |
Triglyceridec | -0.15 | 0.120 |
HDL-cholesterol | 0.03 | 0.780 |
LDL-cholesterol | -0.04 | 0.650 |
Estimated GFR | 0.20 | 0.040 |
Leukocyte | -0.14 | 0.160 |
Hs-CRPc | -0.22 | 0.030 |
TSH | -0.13 | 0.120 |
25-OH vitamin D | 0.17 | 0.090 |
Total energy intake | -0.05 | 0.610 |
Protein intake | 0.08 | 0.460 |
Isoflavone intakec | 0.17 | 0.150 |
Table 3.
Variables | β | Standard error | F-value | P |
---|---|---|---|---|
Equol production | 47.864 | 10.446 | 42.83 | 0.002 |
Age | -1.141 | 0.364 | 6.15 | 0.020 |
Total lean body mass | 4.483 | 1.577 | 7.25 | 0.010 |
All variables remaining in the model are significant at the 0.15 level. No other variables met the 0.15 significance level for entry into the model; R2 for telomere length was 0.81; Variables included in the stepwise model were body mass index; waist-hip ratio; total body fat; systolic blood pressure; estimated GFR; fasting glucose; hs-CRP; 25-OH vitamin D; alcohol consumption; regular exercise; and use of anti- hypertensive, anti-diabetic, and lipid lowering agents.